Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? A in vivo quantitative [ 123I]epidepride SPET study of amisulpride-treated patients

American Journal of Psychiatry

Volumn 160, Issue 8, 2003, Pages 1413-1420

  Bressan, Rodrigo A ^a   Erlandsson, Kjell ^b   Jones, Hugh M ^b   Mulligan, Rachel ^b   Flanagan, Robert J ^b   Ell, Peter J ^b   Pilowsky, Lyn S ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EPIDEPRIDE; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DRD3 PROTEIN, HUMAN; DRUG DERIVATIVE; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE; SULPIRIDE; SULTOPRIDE;

ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; HUMAN; KINETICS; LIMBIC CORTEX; PRIORITY JOURNAL; PSYCHOSIS; QUANTITATIVE ANALYSIS; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; THALAMUS; ADULT; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; LIMBIC SYSTEM; MALE; METABOLISM; MIDDLE AGED; SCHIZOPHRENIA; SCINTISCANNING; TEMPORAL LOBE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; CORPUS STRIATUM; FEMALE; HUMANS; IODINE RADIOISOTOPES; LIMBIC SYSTEM; MALE; MIDDLE AGED; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SULPIRIDE; TEMPORAL LOBE; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0041880367     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.8.1413     Document Type: Article

References (40)

1. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33:227-235
2. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520
3. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW: Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET study. Psychol Med 1993; 23:791-797
4. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NP, Kerwin RW: Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340:199-202
5. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
6. Lidow MS, Goldman-Rakic PS: A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 1994; 91:4353-4356
7. Meltzer HY: New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacology 1988; 1:193-196
8. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001; 158:360-369
9. Strange PG: Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53:119-133
10. Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C, Kerwin RW, Pilowsky LS: In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs: [123I]epidepride SPET study. Br J Psychiatry 1999; 175:231-238
11. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179:503-508
12. Kessler RM, Ansari MS, Li R, Dawant B, Lee M, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2 receptors by atypical antipsychotic drugs. J Nucl Med 2002; 43:15P
13. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW: Limbic selectivity of clozapine. Lancet 1997; 350:490-491
14. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS: Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride SPET study. Psychopharmacology (Berl) 2000; 150:132-140
15. 123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 2000; 177:408-415
16. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS: Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 2003; 23:5-14
17. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B: Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280:83-97
18. 2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155:505-508
19. Leucht S, Pitschel-Walz G, Engel RR, Kissling W: Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159:180-190
20. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
21. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
22. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
23. Addington D, Addington J, Maticka-Tyndale E, Joyce J: Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992; 6:201-208
24. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33:766-771
25. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
26. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
27. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
28. Lange K, Fessler JA: Globally convergent algorithms for maximum a posteriori transmission tomography. IEEE Trans Image Process 1995; 4:1430-1438
29. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S: A practical method for position-dependent Compton-scatter correction in single emission CT. IEEE Trans Med Imaging 2002; 10:408-412
30. Chang LT: A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; 25:638-643
31. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain: Three-Dimensional Proportional System. New York, Thieme Medical, 1988
32. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4:153-158
33. Camps M, Cortes R, Gueye B, Probst A, Palacios JM: Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989; 28:275-290
34. Martinot JL, Paillère-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Maziere B: In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996; 124:154-158
35. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, Maziere B, Paillère-Martinot ML: In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21:207-214
36. Olsson H, Farde L: Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. Neuroimage 2001; 14:936-945
37. Erlandsson K, Bressan RA, Mulligan RM, Ell PJ, Cunningham VJ, Pilowsky LS: Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage (in press)
38. Farde L, Wiesel FA, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71-76
39. Tiihonen J, Kuoppamki M, Nagren K, Bergman J, Eronen E, Syvalahti E, Hietala J: Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 1996; 126:277-280
40. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38